**Publications Eric Ronken**

Eric.ronken@gmail.com

**Scientific publications (full papers):**

1. Sphingosine-1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier. R van Doorn, MA Lopes Pinheiro, G kooij, K Lakemn, B van het Hof, SM van der Pol, J van Horssen, P van der Valk, E van der Kam, **E Ronken**, A Reijerkerk, HE de Vries. J Neuroinflamm. 9: 133-148 (2012).

2. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. R Van Doorn, J Van Horssen, D Verzijl, M Witte, **E Ronken**, B Van Het Hof, K Lakeman, CD Dijkstra, P Van Der Valk, A Reijerkerk, AE Alewijnse, SL Peters, HE De Vries. Glia 58:1465-76 (2010).

3. Adaptations in pre- and post-synaptic 5HT1A receptor function and cocaine supersensitivity in serotonin transporter knock-out rats. JR Homberg, SF de Boer, HS Raaso, JD Olivier, M Verheul, **E Ronken**, AR Cools, BA Ellenbroek, ANM Schoffelmeer, LJ Vanderschuren, TJ de Vries, E Cuppen. Psychopharmacol 200: 367-380 (2008)

4. Protective effects of peroxiredoxin-1 at the injured blood brain barrier. G Schreibelt, J van Horssen, RF Haseloff, A Reijerkerk, SM van der Pol, O Nieuwenhuizen, E Krause, IE Blasig, CD Dijkstra, **E Ronken**, HE de Vries. Free Radic Biol Med 45:256-264 (2008)

5. Serotonin transporter deficiency in the rat increases behavioral impulse control. J Homberg, T Pattij, MC Janssen, **E Ronken**, SF de Boer, ANM Schoffelmeer, E Cuppen. Eur J Neurosci 26:2066-2073 (2007)

6. Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling. G Schreibelt, G Kooij, A Reijerkerk, R Van Doorn, SI Gringhuis, S Van der Pol, BB Weksler, AI Romero, PO Couraud, J Piontek, IE Blasig, CD Dijkstra, **E Ronken**, HE De Vries. FASEB J 13: 3666-3676 (2007)

7. Characterization of the serotonin transporter knockout rat: A selective change in the functioning of the serotonergic system.. JR Homberg, JDA Olivier, BMG Smits, JD Mul, J Mudde, M Verheul, OFM Nieuwenhuizen, AR Cools, **E Ronken** ,T Cremers, ANM Schoffelmeer, BA Ellenbroek, E Cuppen. Neurosci, 146: 1662-1667 (2007).

8. In situ entry of oligonucleotides into brain cells can occur through a nucleic acid channel: options for effectuating antisense therapy in the brain. Shi F, Swinny J, **Ronken E**, Hoekstra D. Oligonucleotides 17: 123-133 (2007).

9.Neonatal basolateral amygdala lesions affect monoamine and cannabinoid brain systems in adult rats. H Bouwmeester, MAFM Gerrits, JG Roozemond, J Snapper, **E Ronken**, CG Kruse, HGM Westenberg, JM Van Ree. Neuropsychopharmacol, 1-13 (2006)

10. In vitro Characterization of SLV308 (7-[4-Methyl-1-Piperazinyl]-2(3H)-Benzoxazolone, Monohydrochloride): a Novel Partial Dopamine D2 and D3 Receptor Agonist and Serotonin 5-HT1A Receptor Agonist. JC Glennon, GJM van Scharrenburg, **E Ronken**, MB Hesselink, JH Reinders, M van der Neut, SK Long, RW Feenstra and AC McCreary. Synapse, 60:599-608 (2006)

11. Differential regulation of the CXCR2 chemokine network in rat brain trauma: implications for neuroimmune interactions and neuronal survival. A Vallès, L Grijpink-Ongering, FM de Bree, T Tuinstra,**E. E. Ronken** .Neurobiology of Disease 22: 312-322 (2006)

12. Structure-activity studies on the corticotrophin releasing factor antagonist astressin, leading to a minimal sequence necessary for antagonistic activity. Rijkers DTS, Kruijtzer JAW, van Oostenbrugge M, **Ronken E**, den Hartog JAJ, Liskamp RMJ. Chem BioChem 5: 340-348(2004)

13. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists. JHM Lange, HKAC Coolen, HH van Stuivenberg, JAR Dijksman, AHJ Herremans, **E Ronken**, HG Keizer, K Tipker, AC McCreary, W Veerman, HC Wals, B Stork, PC Verveer, AP den Hartog , NMJ de Jong, TJP Adolfs,J Hoogendoorn, CG Kruse. J Med Chem 47: 627-643 (2004)

14. Antisense oligonucleotides reach mRNA targets via the RNA matrix: downregulation of the 5-HT1A receptor. F ShiWH VisserH, NMJ de Jong, RSB Liem, **E Ronken**, D Hoekstra. Exp. Cell Res 291:313-325(2003)

15. Effects of neonatal amygdala lesions on [125I] neurotensin binding in specific brain areas of adult rat. H Bouwmeester, J Snapper, **E Ronken**, CG Kruse, JM Van Ree. Eur J Neurosci. 2003 Mar;17(6):1319-22.

16. Overexpression of corticotropin-releasing hormone in transgenic mice and chronic stress-like autonomic and physiological alterations. A Dirks, L Groenink, JA Bouwknecht, TH Hijzen, J Van Der Gugten, **E Ronken**, JS Verbeek, JG Veening, PJ Dederen, A Korosi, LF Schoolderman, EW Roubos, B Olivier.
Eur J Neurosci. 2002 16(9):1751-1760(2002)

17. Design, Synthesis and Biological Activity of Rigid Cannabinoid CB1 Receptor Antagonists. AR Stoit, JHM Lange, AP den Hartog, **E Ronken**, K Tipker, HH van Stuivenberg, JAR Dijksman, HC Wals, and CG Kruse. Chem. Pharm. Bull., 50:1109-1113(2002)

18. SLV308: A Novel antiParkinsonian agent with antidepresssant and anxiolytic properties. A McCreary, E Ronken, J van der Heyden, A Herremans, T Tuinstra, S Long, GJM van Scharrenburg. In Parkinson’s disease, **E. Ronken** and GJM van Scharrenburg (Eds). Pp 51-58, 2002

19. Reactive oxygen species enhance the migration of monocytes across the blood-brain barrier in vitro. A Van der Goes, D Wouters, S Van Der Pol, R Huizinga, **E Ronken**, P Adamson, J Greenwood, CD Dijkstra, HE De Vries:. FASEB J 15(10):1852-1854(2001)

20. SLV308, Antiparkinsonian Antidepressive, AnxiolyticPartial Dopamine D2 Agonist 5-HT1A Agonist R Feenstra, **E Ronken**, T Koopman, M de Vries, A McCreary, M Stoker, K. van Charldorp, S Long, GJM van Scharrenburg. Drugs of the Future 26: 128-132 (2001)

21. Short and long-term plasticity after lesioning of the cell body or terminal field area of the dopaminergic mesocorticolimbic system in the rat. PE Vos, HW Steinbush, **E Ronken**, JM van Ree. Brain Res 831: 237-247 (1999).

22. Acute effects of oxidized low density lipoprotein on metabolic responses in macrophages. HE de Vries, **E Ronken**, JH Reinders, B Buchner, TJ van-Berkel, J Kuiper. FASEB J 12 (1): 111-118 (1998).

23. Mutational analysis of the potential phosphorylation sites for protein kinase C on the CCK-A receptor. RLL Smeets, MA Fouraux, W Pouwels, SE van Ernst-de Vries, **E Ronken**, JJHHM De Pont, PHGM Willems. Br J Pharmacol. 123: 1189-1197 (1998).

24. Ultrasonic vocalizations in pups: effects of serotonergic ligands. B Olivier, HE Molewijk, JAM vd Heyden, R van Oorschot, **E Ronken**, J Mos, KA Miczek. Neuroscience and Biobehav Revs. 23: 215-227 (1998).

25. Rat pup ultrasonic vocalization: effects of benzodiazepine receptor ligands. B Olivier, E. Molewijk, R van Oorschot, J van der Heyden, **E Ronken**, J Mos. Eur J Pharmacol 358: 117-128 (1998).

26. Pattern of c-fos expression induced by fluvoxamine are different after acute vs. chronic oral administration. JG Veening, LM Coolen, WPJM Spooren, H Joosten, R van Oosrschot, J Mos, **E Ronken**, B Olivier.. Eur Neuropsychopharmacol 8: 213-226 (1998).

27. Anxiolytic effects of flesinoxan in the stress-induced hyperthermia paradigm in singly-housed mice are 5-HT1A receptor mediated. B Olivier, TJJ Zethof, **E Ronken**, JAM vd Heyden.. Eur J Pharmacol., 342:177-182(1998).

28. In vitro and in vivo characterization of newly developed iodinated 1-[2-[bis(4-fluorophenyl)-methoxy]ethyl]-piperazine derivatives in rats: limited value as dopamine transporter SPECT ligands. LJ Rijks, J Booij, T Doornbos, GJ Boer, **E Ronken**, K de Bruin, RJ Vermeulen, AG Janssen, EA van Royen. Synapse.23: 201-7 (1996).

29. Dopamine displays an identical apparent affinity towards functional dopamine D1 and D2 receptors in rat striatal slices: possible implications for the regulatory role of D2 receptors. Schoffelmeer ANM, F Hogenboom, AH Mulder, **E Ronken**, JC Stoof, B. Drukarch. Synapse 17: 190-195 (1994).

30. Chronic activation of mu- and kappa-opioid receptors in cultured catechol-aminergic neurons from rat brain causes neuronal supersensitivity without receptor desensitization. **E Ronken**, AH Mulder, ANM Schoffelmeer. J Pharmacol Exp Ther. 268: 595-599 (1994).

31. Glucocorticoid and mineralocorticoid receptors differentially modulate cultured dopaminergic neurons of rat ventral mesencephalon. **E Ronken**, AH Mulder, ANM Schoffelmeer. Eur J Pharmacol 263: 149-156 (1994).

32. Repeated and chronic morphine administration causes differential long-lasting changes in dopaminergic neurotransmission in rat striatum without changing its delta- and kappa-opioid receptor regulation. GH Tjon, TJ de Vries, **E Ronken**, F Hogenboom, G Wardeh, AH Mulder, ANM Schoffelmeer. Eur J Pharmacol. 252: 205-212 (1994)

33. Opioid receptor-mediated inhibition of evoked catecholamine release from cultured neurons of rat ventral mesencephalon and locus coeruleus. E Ronken, FL v Muiswinkel, AH Mulder, ANM Schoffelmeer Eur J Pharmacol 230: 349-355 (1993)

34. Interacting presynaptic kappa-opioid and GABAA receptors modulate dopamine release from rat striatal synaptosomes. E Ronken, AH Mulder, ANM Schoffelmeer. J Neurochem 61: 1634-1639 (1993)

35. Topography and characteristics of specific binding sites for non-opioid ?-type endorphins as studied by autoradiography with [35S]Met-desenkephalin--endorphin. E Ronken, VM Wiegant, FM Kaspersen, JW van Nispen, Th de Boer, HW Bruning, CJJ Rust, JADM Tonnaer. Brain Res 615: 63-70 (1993)

36. -Endorphins and schizophrenia. VM Wiegant, E Ronken, G Kovacs, D de Wied. Prog Brain Res 93: 433-453(1992).

37. Binding sites for non-opioid gamma-type endorphins in brain structures fo the mesocorticolimbic feedback circuit. VM Wiegant, E Ronken, Th de Boer, JADM Tonnaer. Prog Clin Biol Res 328: 29-32 (1990)

38. Autoradiographic evidence for binding sites for des-enkephalin--endorphin (ORG 5878) in rat forebrain. E Ronken, JADM Tonnaer, Th de Boer, VM Wiegant. Eur J Pharmacol 162:189-191 (1989)

**Books and chapters**

Trophic factors and the blood-brain barrier. **E Ronken**, GJM van Scharrenburg. In “Blood-brain barrier and microenvironment” HE de Vries and A. Prat (Eds); Marcel Dekker, New York, 2005. pp. 71 - 85

Parkinson’s disease. 1st Solvay Pharmaceuticals Conferences, 2002. **E Ronken** and GJM van Scharrenburg, eds. IOS Press. ISBN 1 58603 207 0

Regulation of Glial Cell line-Derived Neurotrophic Factor (GDNF) for dopamine conservation in models for Parkinson’s disease. **E. Ronken**, D McCrossan, J Venema. In Parkinson’s disease, E. Ronken and GJM van Scharrenburg (Eds). Pp 148-156, 2002

SLV308: A Novel anti-Parkinsonian agent with antidepresssant and anxiolytic properties. AC McCreary, **E Ronken**, J van der Heyden, A Herremans, T Tuinstra, S Long, GJM van Scharrenburg. In Parkinson’s disease, E. Ronken and GJM van Scharrenburg (Eds). Pp 51-58, 2002

The 5-HT2-type receptor family. **E Ronken**, In 'Serotonin receptors and their ligands', B Olivier, I van Wijngaarden and W Soudijn (Eds). Elsevier Science BV, Amsterdam, 1997. pp. 199-214